|
|
| |
Virtual Meeting - 2008 Gastrointestinal Cancers Symposium
|
|
Presentations from the 2008 Gastrointestinal Cancers Symposium have been grouped into areas of interest, and to support evidence-based clinical decision. Presentations with relevance for multiple diagnoses or clinical themes will have multiple listings.
| Search all gastrointestinal cancers Virtual Meeting presentations |
|
Gastroesophageal Cancers
Stem Cells and Their Role in Gastric Cancer James R. Goldenring, MD, PhD Screening and Prevention
Screening/Surveillance of Individuals at Risk for Esophageal Adenocarcinoma – Does it Matter? Chin Hur, MD, MPH
The Changing Epidemiologic Landscape of Esophageal and Gastric Cancer William J. Blot, PhD
Abstract No: 2 - Barrett's Esophagus: Prevalence of central adiposity, metabolic syndrome, and a pro-inflammatory state
Esophageal Cancer Treatment
Multimodality Therapy for Esophageal Squamous Cell Carcinoma -- Is Surgery a Footnote? Rebecca Wong, MBChb
Discussion Esophageal Abstracts Susan G. Urba, MD
Abstract No: 9 - Long term results of the MRC OEO2 randomized trial of surgery with or without preoperative chemotherapy in resectable esophageal cancer
Abstract No: 10 - A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for localized squamous cell carcinoma of the thoracic esophagus (JCOG 9907)
Abstract No: 4 Post-treatment 18-FDG PET scans in esophageal cancer patients receiving combination chemoradiation: Too much information?
Gastroesophageal and Gastric Cancer Treatment
Molecular Therapies in Esophageal and Gastric Cancer: Are We on Target? Josep Tabernero, MD
Tailoring Multimodality Treatment for Gastroesophageal Junction Adenocarcinoma Stephen Swisher, MD
Endoscopic Resection Techniques for Esophageal and Gastric Cancer Irving Waxman, MD
Abstract No: 5 - Randomized phase III study of irinotecan plus S-1 (IRIS) versus S-1 alone as first-line treatment for advanced gastric cancer (GC0301/TOP-002).
Abstract No: 6 - A randomized phase III trial comparing mitomycin-C plus short-term doxifluridine (Mf) versus mitomycin-C plus long-term doxifluridine plus cisplatin (MFP) after curative resection of advanced gastric cancer (AMC 0201)
Colorectal Cancer
Tumor Biology
Colorectal Cancer Stem Cells -- Implications for Treatment Catherine A. O'Brien, BSc, MD, MSc, FRCSC
Circulating Tumor Cells: Are They Predictive Markers? Neal J. Meropol, MD
Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors: Is It Time to Start Selecting Patients? Heinz-Josef Lenz, MD
Prevention, Screening, and Staging
Abstract No: 275 Association between insurance status and stage at diagnosis for patients with colorectal cancer
Abstract No: 276 - Initial evaluation of colon cancer-specific antigen-2 (CCSA-2) as a serum marker for colorectal cancer.
Abstract No: 275 - Association between insurance status and stage at diagnosis for patients with colorectal cancer
Controversies and Advances in Colonoscopic Colorectal Cancer Screening Randall W. Burt, MD
Abstract No: 282 - A prospective comparison of colonoscopy, sigmoidoscopy, CT colonography, and stool tests in an average risk population.
Adjuvant
Abstract No: 274 -Capecitabine versus 5-FU/LV in stage III colon cancer: Updated 5-year efficacy data from X-ACT trial and preliminary analysis of relationship between hand-foot syndrome (HFS) and efficacy
Abstract No: 277 - Does UGT1A1*28 homozygosity predict for severe toxicity in patients treated with 5-fluorouracil (5-FU)-irinotecan (IRI)? Results of the PETACC 3-EORTC 40993-SAKK 60/00 trial comparing IRI/5-FU/folinic acid (FA) to 5-FU/FA in stage II-III colon cancer.
Metastatic
Integration of Epidermal Growth Factor Receptor Targeting into First Line Therapy: Is it Time? Eric Van Cutsem, MD
Abstract No: 273- An updated analysis of safety and efficacy of oxaliplatin (Ox)/bevacizumab (bev) +/- panitumumab (pmab) for first-line treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized, controlled trial (PACCE)
Abstract No: 279 Interim results from PACCE: Irinotecan (Iri)/bevacizumab (bev) ± panitumumab (pmab) as first-line treatment (tx) for metastatic colorectal cancer (mCRC)
Abstract No: 280 Effect of intravenous (IV) calcium and magnesium (Ca/Mg) versus placebo on response to FOLFOX+bevacizumab (BEV) in the CONcePT trial.
Abstract No: 281 Phase III trial of chemotherapy with or without irinotecan in the front-line treatment of metastatic colorectal cancer in elderly patients (FFCD 2001-02 trial): Results of a planned interim analysis.
Abstract No: 278 - Panitumumab (pmab) efficacy and patient-reported outcomes (PRO) in metastatic colorectal cancer (mCRC) patients (pts) with wild-type (WT) KRAS tumor status.
Rectal
Diagnosing and Staging Rectal Cancer: Endoscopic Ultrasound vs. Pelvic MRI Gina Brown, MD
Pancreatic cancer
What Will It Take to Diagnose Pancreatic Cancer Early? Ralph H. Hruban, MD
Controversies in the Diagnosis and Management of Cystic Neoplasms of the Pancreas Pascal Hammel, MD
Controversies in the Diagnosis and Management of Cystic Neoplasms of the Pancreas Keith D. Lillemoe, MD, FACS
Abstract No: 124 - Benefit of adjuvant chemoradiation therapy for pancreatic adenocarcinoma: The Johns Hopkins Hospital--Mayo Clinic collaborative study of 1,045 patients.
Abstract No: 125 - ACOSOG Z05031: Initial report of a multicenter, phase II trial of a novel chemoradiation protocol using cisplatin, 5-FU, and alpha- interferon as adjuvant therapy for resected pancreas cancer.
Hepatobiliary
Hepatocellular Carcinoma
Identifying High Risk Populations for Hepatocellular Carcinoma: What is the Standard for Screening? Eugene R. Schiff, MD
Imaging of Primary Hepatic Tumors: Differential Diagnosis and Resectability Criteria Valérie Vilgrain, MD
Who Should Undergo Liver Transplant for Hepatocellular Carcinoma and Cholangiocarcinoma? David A. Geller, MD, FACS
Chemoradiation Therapy for Liver Tumors: Asian Perspective Jinsil Seong, MD, PhD
Hepatic Metastases
No Chemotherapy Before Surgery for Hepatic Metastases Kenneth Tanabe, MD
Chemotherapy Before Surgery for Hepatic Metastases John L. Marshall, MD
Abstract No: 283 - Two-stage hepatectomy for irresectable colorectal cancer liver metastases: A 14-year experience.
GIST
Gastrointestinal Stromal Tumor: Exploiting Molecular Mechanisms to Improve Patient Care Robert G. Maki, MD, PhD
Abstract No: 3 - Correlation of imatinib plasma levels with clinical benefit in patients (Pts) with unresectable/metastatic gastrointestinal stromal tumors (GIST)
Abstract No: 7 - Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal tumors (GIST): A phase II trial of the University of Chicago Phase II Consortium
Abstract No: 8 Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: The U.S. Intergroup phase II trial ACOSOG Z9000.
GI Neuroendocrine tumors
Current Approaches to the Management of Pancreatic Endocrine Tumors and GI Carcinoids Matthew Kulke, MD
Anal Cancer
Current Management of Anal Cancer Christopher Willett, MD
Peritoneal Carcinomatosis
Novel Approaches to the Management of Peritoneal Carcinomatosis Paul F. Mansfield, MD
|
|
|
|
|
|
Printer Friendly
E-Mail Article
